Clinical Trial Update: Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 safety study of oral pirfenidone in patients with idiopathic pulmonary fibrosis and pulmonary fibrosis has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Drugs mentioned

• Esbriet (pirfenidone)
• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Genentech, Inc. | Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2016-03-09